StockData
Zevra Therapeutics, Inc. logo

Zevra Therapeutics, Inc. (ZVRA) stock

ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.40+0.15 (+1.62%)

Close on Nov 17, 2026Market cap $558.21MP/E 10.1Yield –

Zevra Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Zevra Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $14.93M, down 42.6% year over year. For fiscal 2025 it was $12.74M, down 69.7% from the year before. Over ten years it grew -0.9% a year on average. The highest annual figure on record is $42.10M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$12.74M-69.7%
FY2024Dec 31, 2024$42.10M+5.8%
FY2023Dec 31, 2023$39.81M+101.0%
FY2022Dec 31, 2022$19.80M+94.9%
FY2021Dec 31, 2021$10.16M+14.9%
FY2020Dec 31, 2020$8.84M-54.5%
FY2019Dec 31, 2019$19.42M-53.5%
FY2018Dec 31, 2018$41.76M+102.8%
FY2017Dec 31, 2017$20.59M+0.6%
FY2016Dec 31, 2016$20.47M+47.0%
FY2015Dec 31, 2015$13.93M+16.9%
FY2014Dec 31, 2014$11.92M+253.9%
FY2013Dec 31, 2013$3.37M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$4.49M+30.7%
Q1 FY2026Mar 31, 2026$4.39M+34.8%
Q4 FY2025Dec 31, 2025$2.62M-68.6%
Q3 FY2025Sep 30, 2025$3.43M-68.6%
Q2 FY2025Jun 30, 2025$3.43M-67.4%
Q1 FY2025Mar 31, 2025$3.26M-73.5%
Q4 FY2024Dec 31, 2024$8.35M-26.9%
Q3 FY2024Sep 30, 2024$10.95M-11.0%
Q2 FY2024Jun 30, 2024$10.52M+41.5%
Q1 FY2024Mar 31, 2024$12.28M+41.8%
Q4 FY2023Dec 31, 2023$11.42M+74.6%
Q3 FY2023Sep 30, 2023$12.30M+128.4%
Q2 FY2023Jun 30, 2023$7.43M+55.0%
Q1 FY2023Mar 31, 2023$8.66M+180.8%
Q4 FY2022Dec 31, 2022$6.54M+132.9%
Q3 FY2022Sep 30, 2022$5.39M+140.5%
Q2 FY2022Jun 30, 2022$4.80M+68.4%
Q1 FY2022Mar 31, 2022$3.08M+36.1%
Q4 FY2021Dec 31, 2021$2.81M-8.0%
Q3 FY2021Sep 30, 2021$2.24M+31.0%
Q2 FY2021Jun 30, 2021$2.85M+45.8%
Q1 FY2021Mar 31, 2021$2.27M+6.5%
Q4 FY2020Dec 31, 2020$3.05M+23.9%
Q3 FY2020Sep 30, 2020$1.71M-52.7%
Q2 FY2020Jun 30, 2020$1.95M-59.3%
Q1 FY2020Mar 31, 2020$2.13M-75.1%
Q4 FY2019Dec 31, 2019$2.47M-60.9%
Q3 FY2019Sep 30, 2019$3.62M-72.9%
Q2 FY2019Jun 30, 2019$4.80M-54.2%
Q1 FY2019Mar 31, 2019$8.53M-26.7%
Q4 FY2018Dec 31, 2018$6.30M+13.9%
Q3 FY2018Sep 30, 2018$13.33M+111.8%
Q2 FY2018Jun 30, 2018$10.49M+125.5%
Q1 FY2018Mar 31, 2018$11.64M+182.9%
Q4 FY2017Dec 31, 2017$5.54M-30.5%
Q3 FY2017Sep 30, 2017$6.29M+46.8%
Q2 FY2017Jun 30, 2017$4.65M–
Q1 FY2017Mar 31, 2017$4.11M–
Q4 FY2016Dec 31, 2016$7.96M–
Q3 FY2016Sep 30, 2016$4.29M–

More Zevra Therapeutics figures

See a number that looks wrong?